# US 2019/0314391 A1 · Compositions for oral administration of zoledronic acid or related compounds for treating disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314391 A1
- Document ID: US20190314391A1
- Status: Published application
- Kind: A1
- Application number: 16/452,910
- Filed: 2019-06-26
- Published: 2019-10-17
- Earliest claimed: 2012-05-14
- Assignees: Antecip Bioventures II LLC
- Applicants: Antecip Bioventures II LLC
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US20190314391A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 31/663: Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- C07F 9/6506: having the nitrogen atoms in positions 1 and 3
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

## Claims

### Claim 1

A method of treating arthritis comprising orally administering a zoledronic acid to a human being suffering from arthritis, wherein the zoledronic acid is in an acid form or a salt form, wherein the human being is fasted for at least 2 hours prior to receiving the zoledronic acid and the human being is fasted for at least 1 hour after receiving the zoledronic acid, wherein the zoledronic acid has a bioavailability that is 1.1% to about 4%, and wherein the human being experiences pain relief as a result of receiving the zoledronic acid.

### Claim 2 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a bioavailability that is 1.3% to 3%.

### Claim 3 (depends on 1)

The method of claim 1, wherein the human being receives about 0.18 moles of zoledronic acid with each administration of the zoledronic acid.

### Claim 4 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a bioavailability that is 1.4% to 3%.

### Claim 5 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a bioavailability that is 1.5% to 3%.

### Claim 6 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a bioavailability that is 1.6% to 3%.

### Claim 7 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a bioavailability that is 1.8% to 3%.

### Claim 8 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a bioavailability that is 1.8% to 4%.

### Claim 9 (depends on 1)

The method of claim 1, wherein the arthritis affects a knee, an elbow, a wrist, a shoulder, or a hip.

### Claim 10 (depends on 1)

The method of claim 1, wherein each dose of the zoledronic acid is orally administered in a manner that provides an AUC0-inf of zoledronic acid of about 100 ng·h/mL to about 200 ng·h/mL.

### Claim 11 (depends on 1)

The method of claim 1, wherein the human being is fasted in a manner that maximizes bioavailability.

### Claim 12 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a 24 hour sustained plasma factor that is about 10 to about 15.

### Claim 13 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a 24 hour sustained plasma factor that is about 12 to about 15.

### Claim 14 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a 24 hour sustained plasma factor that is at least twice that of 1 mg of zoledronic acid administered intravenously.

### Claim 15 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a 48 hour sustained plasma factor that is at least twice that of 1 mg of zoledronic acid administered intravenously.

### Claim 16 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a 24 hour sustained plasma factor that is at least 1.2 times that of 4 mg of zoledronic acid administered intravenously.

### Claim 17 (depends on 1)

The method of claim 1, wherein the zoledronic acid is orally administered in a manner that results in a 48 hour sustained plasma factor that is at least twice that of 4 mg of zoledronic acid administered intravenously.

### Claim 18

A method of providing zoledronic acid to a human being comprising orally administering a zoledronic acid to a human being in need of treatment with zoledronic acid, wherein the zoledronic acid is in a salt form, wherein the human being is fasted for at least 2 hours prior to receiving the zoledronic acid and the human being is fasted for at least 1 hour after receiving the zoledronic acid, and wherein the zoledronic acid has a bioavailability that is 1.1% to about 4%.

### Claim 19 (depends on 18)

The method of claim 18, wherein the zoledronic acid is orally administered in a dosage form that contains at least 20% zoledronic acid in a disodium salt form by weight.

### Claim 20 (depends on 18)

The method of claim 18, wherein the zoledronic acid is orally administered in a dosage form that contains at least 30% zoledronic acid in a disodium salt form by weight.

### Claim 21 (depends on 18)

The method of claim 18, wherein the zoledronic acid is orally administered in a dosage form that contains about 50 mg to about 100 mg of zoledronic acid in a disodium salt form.

### Claim 22 (depends on 18)

The method of claim 18, wherein the zoledronic acid is orally administered in a dosage form that contains at least 40% zoledronic acid in a disodium salt form by weight.

### Claim 23 (depends on 18)

The method of claim 18, wherein the zoledronic acid is orally administered in a dosage form that contains at least 50% zoledronic acid in a disodium salt form by weight.

### Claim 24 (depends on 18)

The method of claim 18, wherein the zoledronic acid is orally administered in a dosage form that contains at least 60% zoledronic acid in a disodium salt form by weight.

### Claim 25 (depends on 18)

The method of claim 18, wherein the zoledronic acid is orally administered once weekly.

### Claim 26 (depends on 18)

The method of claim 18, wherein the salt form of the zoledronic acid has a water solubility that is about 5% to 50% by weight.

### Claim 27 (depends on 18)

The method of claim 18, wherein the zoledronic acid is orally administered in a manner that results in a 24 hour sustained plasma factor that is about 10 to about 20.

### Claim 28 (depends on 1)

The method of claim 1, wherein each dose of the zoledronic acid is orally administered in a manner that provides an AUC0-inf of zoledronic acid of at least about 100 ng·h/mL.

### Claim 29 (depends on 1)

The method of claim 1, wherein the zoledronic acid has a bioavailability that is 1.1% to 3%.

### Claim 30 (depends on 1)

The method of claim 1, wherein the zoledronic acid has a bioavailability that is 1.1% to 2%.
